Cogent Biosciences (COGT) Change in Account Payables (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Change in Account Payables of $4.2 million for Q1 2026, up 98.04% year-over-year from $2.1 million in Q1 2025, and up 164.98% quarter-over-quarter from -$6.5 million in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Change in Account Payables (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Change in Account Payables for 10 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 98.04% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at -$410000.0 (up 70.94% YoY), while the FY2025 annual figure was -$2.5 million, down 284.76% from the prior year.
- Change in Account Payables climbed to $4.2 million in Q1 2026 per COGT's latest filing, from -$6.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.1 million in Q3 2024 and bottomed at -$6.6 million in Q2 2024.
- Historically, Change in Account Payables has averaged $603588.2 across 5 years, with a median of $787000.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Account Payables jumped 671.51% — and 2024, when it plunged 487.29%.
- Cogent Biosciences' Change in Account Payables stood at $1.7 million in 2022, then plunged by 55.0% to $787000.0 in 2023, then slumped by 487.29% to -$3.0 million in 2024, then slumped by 114.07% to -$6.5 million in 2025, then jumped by 164.98% to $4.2 million in 2026.
- Business Quant data shows COGT's Change in Account Payables at $4.2 million in Q1 2026, -$6.5 million in Q4 2025, and -$596000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 5.92 Bn | 5.92 Bn | - | -6.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.26 Mn |
| Mar 31, 2026 | 4.24 Mn |
| Dec 31, 2025 | -6.53 Mn |
| Sep 30, 2025 | -596,000.00 |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | -6.59 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 787,000.00 |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.99 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Sep 30, 2022 | 601,000.00 |
| Jun 30, 2022 | -523,000.00 |
| Mar 31, 2022 | 532,000.00 |
| Dec 31, 2021 | -866,000.00 |
| Sep 30, 2021 | 2.36 Mn |